Clinical Trial

Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease

Study acronym: NINTOC-TU
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study includes adult patients with systemic sclerosis (SSc) with interstitial lung disease (ILD) to evaluate the efficacy and safety of nintedanib plus tocilizumab combination therapy compared to standard therapy (methotrexate, mycophenolate mofetil) for 56 weeks.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-02-29; most recent amendment 2026-04-07.
Status change: Not Yet Recruiting → Recruiting 2026-04-07
Trial Details
NCT Number NCT06297096
Lead Sponsor National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
Collaborators: Medical Research Agency, Poland
Conditions Systemic Sclerosis, Interstitial Lung Disease
Enrollment 86 participants
Start Date 2025-07-01
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-08